Kidney Transplant Rejection Clinical Trial
Official title:
Clinical Significance of Donor-specific Anti-HLA Antibodies Monitoring in Kidney Transplant Recipients
The aim of this study is to evaluate whether anti-HLA donor-specific antibodies monitoring can be used as an effective tool for stratification of immunological risk in Polish kidney transplant recipients.
Monitoring of immune response is one of the most important goals in the management of the patients after kidney transplantation. Researchers and clinicians are trying to extend the survival of the renal graft. Currently, it is believed that the main cause of late transplant loss is antibody-mediated rejection (ABMR). Anti-HLA donor-specific antibodies (DSA) are a proven risk factor for the development of humoral rejection and transplant loss. Antibodies in sensitized recipients occur before transplantation (preformed) or may develop de novo (in 13% -30% of patients). DSA damage the graft in various mechanisms (complement activation, direct influence on endothelial cells, antibody-dependent cytotoxicity) leading to different clinical-morphological phenotypes. The pathogenicity of DSA is determined by number of their additional characteristics, such as: class, specificity, strength, C1q complement binding, IgG subclass . Monitoring the presence of DSA in the kidney recipient serum with the determination of their characteristics may improve the stratification of the risk of immunological loss of the renal allograft. There is no effective treatment for ABMR, hence DSA monitoring allows for early intervention such as biopsy or modification of immunosuppressive therapy at an early stage of rejection. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04491552 -
TruGraf® Long-term Clinical Outcomes Study
|
||
| Withdrawn |
NCT04560582 -
Immunosuppression Reduction in Failed Allograft Guided by cfDNA
|
||
| Completed |
NCT05747274 -
SRDK0921_ Analytical Performance Study
|
||
| Not yet recruiting |
NCT05482100 -
CLinical Utility of the omnigrAf® biomarkeR Panel In The Care of kidneY Transplant Recipients
|
||
| Recruiting |
NCT06243289 -
Improving KIdney Transplantation With Cellular Therapy Study
|
||
| Not yet recruiting |
NCT06025240 -
Expanding the Scope of Post-transplant HLA-specific Antibody Detection and Monitoring in Renal Transplant Recipients
|
||
| Completed |
NCT04367610 -
Effects of A Standardized Treatment Approach on Kidney Transplant Recipients With Antibody-Mediated Rejection
|
||
| Enrolling by invitation |
NCT06126380 -
Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients
|
Phase 2 | |
| Terminated |
NCT05747053 -
Personalization of Immunosuppressive Treatment for Organ Transplant Recipients
|
||
| Recruiting |
NCT04091984 -
The PROspera Kidney Transplant ACTIVE Rejection Assessment Registry (ProActive)
|
||
| Recruiting |
NCT05335538 -
TruGraf and TRAC In Pediatrics Study
|
||
| Completed |
NCT03663335 -
Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients
|
Phase 2 | |
| Completed |
NCT03652402 -
Precision Risk Stratification in Kidney Transplant Patients - EU-TRAIN
|
||
| Recruiting |
NCT04773392 -
Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR
|
Phase 4 | |
| Completed |
NCT03873623 -
The TOGETHER Project - Kidney
|
||
| Terminated |
NCT02974686 -
Conversion From MPA to Zortress (Everolimus) for GI Toxicity Post-renal Transplantation
|
Phase 4 | |
| Terminated |
NCT04156204 -
Immunosuppressant Medication Dosed Daily After Kidney Transplant
|
Early Phase 1 | |
| Completed |
NCT04601155 -
Transition of Renal Patients Using AlloSure Into Community Kidney Care
|
||
| Completed |
NCT03874299 -
The TOGETHER Project - Kidney RNA-seq Validation
|
||
| Completed |
NCT03965559 -
The Efficacy of Plasmapheresis and Double Filtration Plasmapheresis (DFPP) in Kidney Transplant
|